Stockholm’s BioLamina secures €20M EIB loan



The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The funding will support expanded production of laminin technologies and animal-free drug safety testing methods.


BioLamina, the Stockholm-based biotechnology company that produces the protein scaffolding used to grow stem cells for therapeutic applications, has secured a €20 million loan from the European Investment Bank.

The funding will be used to expand BioLamina’s development of laminin technologies enabling next-generation cell therapies and more advanced, animal-free methods for drug safety testing, according to the EIB’s Stockholm office.

BioLamina sits at an enabling layer of the cell therapy ecosystem: rather than developing therapies directly, it produces the extracellular matrix proteins that allow researchers and companies to grow, expand, and differentiate stem cells reliably outside the body.

Its core product line, Biolaminin®, consists of full-length human recombinant laminin proteins, the same proteins that cells encounter in their natural tissue environment.

Laminins are key structural components of the basement membrane, the protein layer beneath epithelial and endothelial cells, and they trigger cell-type-specific responses including adhesion, survival, differentiation, and organisation.

Most commercial alternatives use truncated or non-human versions of these proteins; BioLamina’s claim is that full-length human laminins provide more biologically faithful conditions and therefore more consistent, reproducible, and clinically compliant cell products.

The therapeutic applications for cells grown on laminin matrices are broad. Cell therapies can potentially be used to treat type 1 diabetes, by generating insulin-producing beta cells,  Parkinson’s disease, heart failure, acute liver failure, and cancer, among other conditions that are currently difficult to treat or have no cure.

BioLamina has collaborated with Novo Nordisk on stem cell therapies for diabetes and has a partnership with Cell X Technologies for iPSC-based therapeutic manufacturing workflows.

Founded in 2008 on research from Dr Karl Tryggvason’s laboratory at the Karolinska Institutet and Duke-NUS Medical School, BioLamina is headquartered in Sundbyberg in Greater Stockholm and employs approximately 100 to 117 people according to different sources.

Its principal shareholders include Swedish investment company Bure Equity AB (via Bure Growth), Lauxera Capital Partners, the Tryggvason family, and Northislet. The company raised €19 million in equity financing in July 2024, led by Lauxera Capital Partners.

The €20 million EIB loan is the company’s first disclosed debt financing and sits within the EIB’s broader BioTechEU mandate, announced in December 2025, to mobilise €10 billion in biotech investment across 2026–27.

CEO Klaus Langhoff-Roos has described BioLamina’s mission as proving that “full-length equals full-function”, a formulation that extends to the company’s drug safety testing products, which provide animal-free alternatives to the animal-derived extracellular matrices that have historically been used in toxicology screening.

The EIB loan will support both arms of the business.



Source link

Leave a Reply

Subscribe to Our Newsletter

Get our latest articles delivered straight to your inbox. No spam, we promise.

Recent Reviews


Do you ever walk past a person on the streets exhibiting mental health issues and wonder what happened to their family? I have a brother—or at least, I used to. I worry about where he is and hope he is safe. He hasn’t taken my call since 2014.

James and his brother as young children playing together before his brother became sick. James is on the right and his brother is on the left.

James and his brother as young children playing together before his brother became sick. James is on the right and his brother is on the left.

When I was 13, I had a very bad day. I was in the back of the car, and what I remember most was the world-crushing sound violently panging off every surface: he was pounding his fists into the steering wheel, and I worried it would break apart. He was screaming at me and my mother, and I remember the web of saliva and tears hanging over his mouth. His eyes were red, and I knew this day would change everything between us. My brother was sick.

Nearly 20 years later, I still have trouble thinking about him. By the time we realized he was mentally ill, he was no longer a minor. The police brought him to a facility for the standard 72-hour hold, where he was diagnosed with paranoid delusional schizophrenia. Concluding he was not a danger to himself or others, they released him.

There was only one problem: at 18, my brother told the facility he was not related to us and that we were imposters. When they let him out, he refused to come home.

My parents sought help and even arranged for medication, but he didn’t take it. Before long, he disappeared.

My brother’s decline and disappearance had nothing to do with the common narratives about drug use or criminal behavior. He was sick. By the time my family discovered his condition, he was already 18 and legally independent from our custody.

The last time he let me visit, I asked about his bed. I remember seeing his dirty mattress on the floor beside broken glass and garbage. I also asked about the laptop my parents had gifted him just a year earlier. He needed the money, he said—and he had maxed out my parents’ credit card.

In secret from my parents, I gave him all the cash I had saved. I just wanted him to be alright.

My parents and I tried texting and calling him; there was no response except the occasional text every few weeks. But weeks turned into months.

Before long, I was graduating from high school. I begged him to come. When I looked in the bleachers, he was nowhere to be seen. I couldn’t help but wonder what I had done wrong.

The last time I heard from him was over the phone in 2014. I tried to tell him about our parents and how much we all missed him. I asked him to be my brother again, but he cut me off, saying he was never my brother. After a pause, he admitted we could be friends. Making the toughest call of my life, I told him he was my brother—and if he ever remembers that, I’ll be there, ready for him to come back.

I’m now 32 years old. I often wonder how different our lives would have been if he had been diagnosed as a minor and received appropriate care. The laws in place do not help families in my situation.

My brother has no social media, and we suspect he traded his phone several years ago. My family has hired private investigators over the years, who have also worked with local police to try to track him down.

One private investigator’s report indicated an artist befriended my brother many years ago. When my mother tried contacting the artist, they said whatever happened between them was best left in the past and declined to respond. My mom had wanted to wish my brother a happy 30th birthday.

My brother grew up in a safe, middle-class home with two parents. He had no history of drug use or criminal record. He loved collecting vintage basketball cards, eating mint chocolate chip ice cream, and listening to Motown music. To my parents, there was no smoking gun indicating he needed help before it was too late.

The next time you think about a person screaming outside on the street, picture their families. We need policies and services that allow families to locate and support their loved ones living with mental illness, and stronger protections to ensure that individuals leaving facilities can transition into stable care. Current laws, including age-based consent rules, the limits of 72-hour holds, and the lack of step-down or supported housing options, leave too many families without resources when a serious diagnosis occurs.

Governments and lawmakers need to do better for people like my brother. As someone who thinks about him every day, I can tell you the burden is too heavy to carry alone.

James Finney-Conlon is a concerned brother and mental health advocate. He can be reached at [email protected].



Source link